Emerging as a leader in non-opioid pain solutions, Latigo Biotherapeutics has secured $135 million in a Series A investment round. The Thousand Oaks, CA-based biotech firm is at the forefront of developing medicines that target pain at its source.

Incubated by Westlake Village BioPartners, the funding round also saw prominent investors like 5AM Ventures, Foresite Capital, and Corner Ventures. With this financial infusion, Latigo Biotherapeutics is gearing up to propel its innovative treatments through the clinical stages.